Denver Peritoneo-Venous Shunt in Refractory Ascites
Total Page:16
File Type:pdf, Size:1020Kb
European Review for Medical and Pharmacological Sciences 2017; 21: 3668-3673 Percutaneous implant of Denver peritoneo- venous shunt for treatment of refractory ascites: a single center retrospective study M. PICCIRILLO1, L. RINALDI2, M. LEONGITO1, A. AMORE1, A. CRISPO1, V. GR ANATA 3, P. APREA4, F. IZZO1 1Department of Abdominal Surgical Oncology and Hepatobiliary Unit, “Istituto Nazionale Tumori IRCCS Fondazione Pascale – IRCCS di Napoli”, Naples, Italy 2Department of Medical, Surgical, Neurological, Metabolic and Geriatric Science, Campania University “Luigi Vanvitelli”, Naples, Italy 3Department of Radiology, “Istituto Nazionale Tumori IRCCS Fondazione Pascale – IRCCS di Napoli”, Naples, Italy 4Department of Anesthesiology, “Istituto Nazionale Tumori IRCCS Fondazione Pascale – IRCCS di Napoli”, Naples, Italy Abstract. – OBJECTIVE: Refractory ascites List of Abbreviations is defined as a lack of response to high doses of diuretics or the development of diuretic related TIPS: Transjugular intrahepatic portosystemic shunts; side effects, which compel the patient to discon- PVS: Peritoneovenous shunt; OS: Overall survival; HR: tinue the diuretic treatment. Current therapeutic Hazard Ratio; DIC: Disseminated intravascular coagu- strategies include repeated large-volume para- lopathy. centesis and transjugular intrahepatic porto- systemic shunts (TIPS). Peritoneovenous shunt (Denver shunt) should be considered for pa- Introduction tients with refractory ascites who are not candi- dates for paracentesis or TIPS. This study pres- Ascites is the most frequent complication of ents our case series in the implant of Denver cirrhosis and it is related to splanchnic vasodilata- peritoneovenous shunt. tion leading to the development of hyperdynamic PATIENTS AND METHODS: Sixty-two pa- circulation, ineffective volemia and activation of tients underwent percutaneous placement of 1 Denver shunt between November 2003 and Ju- the vasoconstrictor system . Ascites is an adverse ly 2014. There were 36 men and 26 women. As- consequence of hemodynamic dysfunctions that 2 cites was secondary to alcoholic cirrhosis in six increase nitric oxide production . Refractory as- patients, cryptogenic cirrhosis in six, and vi- cites is characterized by a failure of response rus-related cirrhosis in fifty of them. Liver cir- to common treatments like a low sodium diet rhosis was classified as Child B in 22 patients and diuretics3. It can be an expression of hepatic and Child C in 40 (no patient was Child A). cirrhosis or of a malignancy in some cases4. The RESULTS: All implants were successfully per- formed. There were no intraoperative problems therapeutic options that are usually considered or lethal complications; our patients were hos- in patients with refractory ascites are repeated pitalized for 2 or 3 days. Postoperative compli- paracenteses or the positioning of Transjugular cations included: infection of the shunt in 3 pa- Intrahepatic Portosystemic Shunts (TIPS). Both tients (4.8%), shunt obstruction in 4 (6.4%) and techniques, however, may induce several side transient abdominal pain in 4 (6.4%). Significant effects. The peritoneovenous shunt (PVS) has symptomatic relief was obtained in all patients. CONCLUSIONS: been reported as an appropriate alternative treat- The percutaneous placement 5 of a Denver shunt is a technically feasible and ment for managing refractory ascites ; it’s an effective method for symptomatic relief of re- implantable device that carries the ascites into the fractory ascites. systemic circulation through a surgically placed subcutaneous plastic cannula with a one-way Key Words: 6,7 Refractory ascites, Cirrhosis, PVS, TIPS, Paracentesis. pressure valve . The aim of this retrospective study was to evaluate the long-term outcomes of 3668 Corresponding Author: Luca Rinaldi, MD; e-mail: [email protected] Denver peritoneo-venous shunt in refractory ascites PVS (Denver shunt, Denver Biomaterials, Gold- Statistical Analysis en, CO, USA) in cirrhotic patients with refractory The univariate risk of death was examined: ascites treated at our institute. overall survival (OS) curves were estimated by the Kaplan-Meier and selected variables were compared using a two-sided log-rank test. The Patients and Methods Cox proportional hazards model was fitted to assess the association between the appearance, Patients or lack thereof, of complications to the procedure Retrospectively, we analyzed sixty-two patients and the risk of death; hazard ratio (HR) and 95% who underwent placement of a Denver shunt for CI was estimated, and adjusted for age, gender the treatment of refractory ascites at our institute and Child-Pugh Score. SPSS statistical package from November 2003 to July 2014. The trial was version 23.0 (SPSS Inc., Chicago, IL, USA) was approved by the “Foundation G. Pascale” Institu- used for all statistical analysis. tional Review Board, Naples, Italy. Patients with hepatocellular carcinoma or other malignancies were excluded from our study. Before surgery, all Results patients had received various medical treatments, including the execution of paracentesis and admin- The cohort consisted of 36 men and 26 wom- istration of diuretics. According to the criteria of the en. The etiology of cirrhosis was alcoholic in International Ascites Club (8), the refractory ascites 6 patients, viral in 50 and cryptogenic in 6; 22 is defined when: (1) the patient did not respond to patients were Child B and 40 were Child C (no sodium chloride restriction (5 g/24 hours) and to the patient was Child A) (Table I). The shunt place- administration of the maximum doses of diuretics ment was successfully performed in all patients (up to 400 mg/day of spironolactone and up to 160 with no perioperative complications (e.g. hemato- mg/day of furosemide); (2) the patient developed ma or bad positioning of the catheter). Using the side effects which in turn precluded the adminis- National Cancer Institute Common Terminology tration of effective doses of diuretics; (3) over the Criteria for Adverse Events (CTCAE version 4.0), last twelve months, he was hospitalized at least 3 we identified major and minor complications: 7 times for having high ascitic fluid. The presence of of the 62 patients (11%) had major complications, hepato-renal syndrome, a bilirubin value more than 3 patients developed a shunt infection and 4 pa- 7 mg/dl or value of PT-INR greater than 2.2 were tients had an obstruction of the shunt (occlusion considered as contraindications to the procedure. of the lumen of the catheter caused by fibrin). 4 of the 62 patients (6%) with minor complica- Methods The procedure is performed under local anes- Table I. Patient Characteristics. thesia. The Denver shunt consists of fenestrated peritoneal catheter, venous catheter, and flexible N 62 (%) 100 pump chamber containing a one-way valve. The pump chamber site was made over the lower Gender Male 36 58.1 rib cage to facilitate manual compression of the Female 26 41.9 pump. The peritoneal end of the shunt was placed Age at the most caudal part of the pelvis, the internal ≤ 69 33 53.2 jugular vein detected by the ultrasound was cho- ≥ 70 29 46.8 sen as a venous access, while the final location Etiology HCV 38 61.3 of the tip of the venous limb of the shunt was HBV 12 19.4 evaluated by fluoroscopy. Before surgery, most HETOC 6 9.7 of the ascites fluid was removed and the patient CRPTO 6 9.7 received antibiotic prophylaxis. All procedures Child were successful and patients were discharged 1-2 Child B (moderate) 22 35.5 Child C (heavy) 40 64.5 days later, without any complications. After the procedure, patients were followed on an outpa- Complications tients’ basis. The measurement of abdominal cir- No complication 51 82.3 cumference was performed before the procedure Abdominal pain 4 6.5 and every 3 days for 30 days. Obstructed/shunt infection 7 11.3 3669 M. Piccirillo, L. Rinaldi, M. Leongito, A. Amore, A. Crispo, V. Granata, P. Aprea, F. Izzo Table II. Univariate analysis OS. Median survival (months) (95% CI) p* Gender < 0.0001 Male 5 (3.2-6.8) Female 13 (11.3-14.6) Age 0.001 ≤ 69 13 (11.6-14.4) ≥ 70 7 (5.3-8.7) Etiology 0.7 HCV 8 (1.9-14.0) HBV 13 (11.9-14.1) HETOC 8 (1.9-14.0) CRPTO 14 (7.2-20.8) Child < 0.0001 Child B (moder) 14 (13.1-14.9) Child C (grave) 7 (5.2-8.8) Complications < 0.0001 No complication 13 (11.9-14.1) Abdominal pain 8 (0.1-18.7) Obstructed/shunt infection 3 (2.4-3.6) *Log-rank test. tions had transient abdominal pain (which was with Child B and 7 months (95% CI 5.2-8.8) in resolved spontaneously) (Table I). All patients patients with Child C (p < 0.001). Based on the showed a reduction in abdominal circumference presence or absence of complications following and body weight. During follow-up, a reduction the procedure, the median survival time was 13 in dosage of diuretics and in the need to carry months (95% CI 11.9 to 14.1) in patients who had out evacuative paracentesis could be seen; in this no complications, 8 months (95% CI 0.1-18.7) in case, the potassium-sparing dose (spironolactone those who had transient pain, and 3 months (95% or potassium canrenoate) needed was 200 mg/ CI 2.4 to 3.6) in those who had blockage or infec- day, while that of loop diuretics (furosemide) was tion from the device (p < 0.0001). No significant 50 mg/day. In reference to the number of para- difference was observed for the etiology (p = 0.7). centeses per month, after positioning the shunt, Prognostic associations of “appearance, or lack 35 patients (56%) did not carry out paracentesis, thereof, of complications related to the procedure” 20 (32%) required a single paracentesis, while 7 was assessed through Cox regression model, a (12%) needed two paracenteses (before the pro- highly significant risk was found for obstructed/ cedure, all patients underwent at least one para- infected shunt, HR = 8.18 95% CI (2.63-25.37), centesis per month).